Replies to post #317848 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

In the end I believe the center of Covid 19 treatment will be an antiviral. As the severity of the disease increases additional drugs will be needed.

The best supportive care will be supplemented by anti inflammatory medications and anticoagulants in severe Covid19 patients

In Covid19 Leronlimab is described by Cytodyn as an anti-flammatory agent, not an antiviral. While it has been shown to be effective in blocking HIV cell entry, I have been unable to find a claim or study which confirms Lenorlimab is an antiviral for Covid19.

Cytodyn states, "To be very clear, leronlimab does not kill the novel coronavirus. It acts as a CCR5 antagonist by blocking pro-inflammatory cytokines, which prevents cytokine storm and thus could be useful in treatment of COVID-19. Leronlimab is administered as a once-a-week injection."

https://www.cytodyn.com/newsroom/press-releases/detail/397/u-s-food-and-drug-administration-fda-grants-emergency

IMO Leronlimab would have to be used with an antiviral to achieve optimal benefit.

In Covid19 Leronlimab's main competition will be other anti-inflammatories such as Dexamethosone.

While Brilacidin's main comperititor will be Remdesivir.

JMO

GLTA, Farrell

"Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn, added, “Leronlimab binds to the CCR5 receptor inhibiting the migration of macrophages and the release on inflammatory cytokines including TNF and IL-6. This release of cytokines is what is commonly referred to as the 'cytokine storm' and is believed to cause profound damage in the lungs in some patients. In addition, leronlimab can block Regulatory T cells (Tregs), which can inhibit the innate immune response against pathogens, into areas of inflammation. These combined mechanisms of action may reduce the morbidity and mortality in moderate to severe cases of COVID-19, preventing the acute respiratory distress syndrome associated with this highly destructive and potentially fatal disease.”

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said, “We are very pleased that we have a potential treatment option for patients affected by COVID-19 infection. To be very clear, leronlimab does not kill the novel coronavirus. It acts as a CCR5 antagonist by blocking pro-inflammatory cytokines, which prevents cytokine storm and thus could be useful in treatment of COVID-19."